The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance. [PDF]
PLoS ONE, 2016 Panitumumab and cetuximab target the epidermal growth factor receptor for the treatment of metastatic colorectal cancer. These therapies provide a significant survival benefit to patients with metastatic colorectal cancer with wild-type RAS.
E Allen Sickmier +5 more
doaj +1 more source
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]
, 2016 Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan +21 more
core +2 more sources
Cell Reports, 2014 Patients with EGFR-mutant lung adenocarcinomas (LUADs) who initially respond to first-generation tyrosine kinase inhibitors (TKIs) develop resistance to these drugs.
Valentina Pirazzoli +18 more
doaj +1 more source
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. [PDF]
PLoS ONE, 2014 BACKGROUND AND PURPOSE:Mutations in the p53 gene are frequently observed in squamous cell carcinoma of the head and neck region (SCCHN) and have been associated with drug resistance.
Mariya Boyko-Fabian +4 more
doaj +1 more source
EGFR mutation positive stage IV non small-cell lung cancer: treatment beyond progression [PDF]
, 2014 Non-small-cell lung cancer (NSCLC) is the leading cause of death from cancer for both men en women. Chemotherapy is the mainstay of treatment in advanced disease, but is only marginally effective. In about 30% of patients with advanced NSCLC in East Asia
Ferdinande, Liesbeth +4 more
core +3 more sources
Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment [PDF]
, 2017 The tumor microenvironment plays a key role in tumor development and progression. Stromal cells secrete growth factors, cytokines and extracellular matrix proteins which promote growth, survival and metastatic spread of cancer cells.
Galemmo, Robert +3 more
core +2 more sources
Frontiers in Oncology, 2020 Cetuximab is a monoclonal antibody that acts as an anti-epidermal growth factor receptor (EGFR) agent. Cetuximab inhibits the phosphorylation and activation of EGFR and blocks downstream signal pathways of EGF/EGFR, including Ras-Raf-MAPK and PI3K-Akt ...
Yijia Wang +7 more
doaj +1 more source
The analysis of the circRNAs in the progress of acquired resistance to Cetuximab
Precision Medical Sciences, 2022 We established a Cetuximab‐resistant cell lines by high‐dose pulse method and searched for differentially expressed circular RNAs by RNA sequencing. Hundreds of circRNAs were altered between sensitive and resistant cells.
Liping Yin, Changwen Jing, Yesong Guo
doaj +1 more source
Triple negative breast cancer: new perspectives for targeted therapies [PDF]
, 2015 Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors.
Caruso, Davide +8 more
core +1 more source
Biomolecules, 2019 Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Cetuximab, a human/mouse chimeric monoclonal antibody, is effective in a limited number of CRC patients because of cetuximab resistance.
Mee Hyun Jeoung +9 more
doaj +1 more source